An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (NYSE: ZYME) has announced its participation in three upcoming investor conferences, showcasing its development of multifunctional biotherapeutics.
At the Stifel 2021 Virtual Healthcare Conference on November 16-17, a fireside chat will occur on November 17 at 1:20 p.m. ET.
The Jefferies London Healthcare Conference will feature a pre-recorded presentation available on November 18.
A fireside chat at the Evercore ISI HEALTHCONx Virtual Conference is scheduled for November 30 at 3:05 p.m. ET.
These events will be webcast and available for replay on Zymeworks' website.
Positive
None.
Negative
None.
VANCOUVER, British Columbia--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences.
Stifel 2021 Virtual Healthcare Conference, November 16th – 17th. Zymeworks is participating in a fireside chat on November 17th at 1:20 p.m. ET.
Jefferies London Healthcare Conference, November 18th – 19th. Zymeworks’ pre-recorded presentation will be available on the Zymeworks’ website listed below on November 18th.
Evercore ISI 4th Annual HEALTHCONx Virtual Conference, November 30th – December 1st. Zymeworks is participating in a fireside chat on November 30th at 3:05 p.m. ET.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next‑generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody which is currently enrolling in two pivotal clinical trials, one for HER2-positive gastroesophageal adenocarcinoma (HERIZON-GEA-01) and one for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) for which it has been granted Breakthrough Therapy designation by the FDA. Zanidatamab is also being evaluated in several Phase 2 clinical trials for HER2-expressing gastroesophageal, colorectal, and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
What are the dates of the upcoming Zymeworks investor conferences?
Zymeworks will participate in three conferences: Stifel 2021 Virtual Healthcare Conference on November 16-17, Jefferies London Healthcare Conference on November 18-19, and Evercore ISI HEALTHCONx Virtual Conference on November 30-December 1.
When is Zymeworks' fireside chat at the Stifel Conference?
The fireside chat at the Stifel 2021 Virtual Healthcare Conference is scheduled for November 17 at 1:20 p.m. ET.
Where can I watch Zymeworks' presentations from the conferences?
Zymeworks' presentations will be webcast live and available for replay on their website.
What is Zymeworks' lead clinical candidate?
Zymeworks' lead clinical candidate is zanidatamab, a bispecific antibody currently in pivotal trials for HER2-positive cancers.
What is the ticker symbol for Zymeworks?
The ticker symbol for Zymeworks is ZYME, listed on the NYSE.
